These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 21129871

  • 1. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA.
    Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
    [Abstract] [Full Text] [Related]

  • 2. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
    Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA.
    Lung Cancer; 2010 Mar; 67(3):311-7. PubMed ID: 19482372
    [Abstract] [Full Text] [Related]

  • 3. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
    Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A.
    J Clin Oncol; 2006 Oct 01; 24(28):4587-93. PubMed ID: 17008700
    [Abstract] [Full Text] [Related]

  • 4. Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
    Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A.
    Cancer Med; 2017 Oct 01; 6(10):2287-2296. PubMed ID: 28941158
    [Abstract] [Full Text] [Related]

  • 5. Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications.
    Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, Ahn MJ, Kim TS, Yi CA, Chung MJ.
    Ann Surg Oncol; 2010 Oct 01; 17(10):2787-94. PubMed ID: 20461469
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. What is the best way to diagnose and stage malignant pleural mesothelioma?
    Zahid I, Sharif S, Routledge T, Scarci M.
    Interact Cardiovasc Thorac Surg; 2011 Feb 01; 12(2):254-9. PubMed ID: 21044972
    [Abstract] [Full Text] [Related]

  • 8. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M.
    Lung Cancer; 2012 Mar 01; 75(3):360-7. PubMed ID: 21937142
    [Abstract] [Full Text] [Related]

  • 9. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
    Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L, Lorenzi E, Gemelli M, Santoro A, Chiti A.
    Eur J Nucl Med Mol Imaging; 2015 Apr 01; 42(5):667-75. PubMed ID: 25403555
    [Abstract] [Full Text] [Related]

  • 10. Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.
    Huang YC, Tu DG, Wu JD, Lee MY.
    Spine (Phila Pa 1976); 2009 Oct 01; 34(21):E780-3. PubMed ID: 19934799
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M, Hoshino T.
    Eur J Radiol; 2012 Dec 01; 81(12):4179-84. PubMed ID: 22884163
    [Abstract] [Full Text] [Related]

  • 12. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH, Kong CB, Lim I, Choi CW, Song WS, Cho WH, Jeon DG, Koh JS, Lee SY, Lim SM.
    J Nucl Med; 2013 Jul 01; 54(7):1053-9. PubMed ID: 23670899
    [Abstract] [Full Text] [Related]

  • 13. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y, Tamura K, Sakata I, Ishida J, Ozeki Y, Tamura A, Uematsu K, Sakai H, Goya T, Kanazawa M, Machida K.
    Oncol Rep; 2012 Feb 01; 27(2):333-8. PubMed ID: 22024889
    [Abstract] [Full Text] [Related]

  • 14. FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy.
    Yoon DH, Baek S, Choi CM, Lee DH, Suh C, Ryu JS, Moon DH, Lee JS, Kim SW.
    Clin Cancer Res; 2011 Aug 01; 17(15):5093-100. PubMed ID: 21673067
    [Abstract] [Full Text] [Related]

  • 15. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.
    Kim BS, Kim IJ, Kim SJ, Pak K, Kim K.
    Onkologie; 2011 Aug 01; 34(6):298-303. PubMed ID: 21625182
    [Abstract] [Full Text] [Related]

  • 16. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, Schnyder P, Luthi F, von Schulthess GK, Leyvraz S.
    Eur J Nucl Med Mol Imaging; 2005 Feb 01; 32(2):153-62. PubMed ID: 15690223
    [Abstract] [Full Text] [Related]

  • 17. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
    Kuribayashi K, Voss S, Nishiuma S, Arakawa K, Nogi Y, Mikami K, Kudoh S.
    Lung Cancer; 2012 Mar 01; 75(3):353-9. PubMed ID: 21890228
    [Abstract] [Full Text] [Related]

  • 18. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
    Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel J, Pons F.
    Q J Nucl Med Mol Imaging; 2011 Dec 01; 55(6):680-7. PubMed ID: 21150863
    [Abstract] [Full Text] [Related]

  • 19. A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
    Higashiguchi M, Suzuki H, Hirashima T, Kobayashi M, Goya S, Okamoto N, Matsuura Y, Tamiya M, Morishita N, Tsumori T, Kawase I.
    Anticancer Res; 2012 Feb 01; 32(2):609-13. PubMed ID: 22287752
    [Abstract] [Full Text] [Related]

  • 20. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
    Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN.
    Clin Lung Cancer; 2010 Jan 01; 11(1):30-5. PubMed ID: 20085865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.